Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC
Question
Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC
Direct answer
Bristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential. — bullish pressure on BMY.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-27
- Published
- 2026-10-28
- Revision
- 1 · 2026-10-28
Cite as: Market Ontology, “Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC”, revision 1, evidence through 2026-10-27. https://marketontology.com/catalysts/2026-10-27/bristol-myers-phase-3-oncology-trial-doubles-progression-free-survival-in-nsclc-a5f8f9
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| BMY | ▲Bull | 1–4 weeks | Policy Shift | 74 |
Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC
Bristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential. — bullish pressure on BMY.
Bristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential.
- SummaryBristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential.
- BMYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- BMY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- BMY price vs. pre-event level
- BMY volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-27Bristol Myers reported positive Phase 3 data for iza-brenBMY
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-27Bristol Myers Squibb lung cancer candidate doubles progression-free survivalBMY
- 2026-10-27Bristol Myers Squibb lung cancer candidate doubles progression-free survivalBMY XBI
- 2026-10-25Bristol Myers and BioNTech post phase 2 data for pumitamig in NSCLCBMY BNTX
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.